Who is sponsoring NCT05330559?

NCT05330559 is sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta.

What drugs are being tested in NCT05330559?

Interventions in NCT05330559: Fluid MAX group.

Is NCT05330559 still recruiting?

NCT05330559 is currently status unknown. Last updated 15 April 2022.

Last reviewed 2022-04-15 · How we verify

NCT05330559: FLUID-MAX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluorescence, Light-microscopy, Ultrasound Integrated / Intraoperative Diagnosis to MAXimise Resection

Status unknown Last updated 15 April 2022

What this trial tests

trial testing Fluid MAX group in Patients With Radiological, Clinical and Anamnestic Picture Compatible With a New Diagnosis of Glioblastoma in 50 participants. Status unknown.

Timeline

8 April 2022

Primary endpoint
8 April 2023

8 April 2024

Quick facts

Lead sponsor	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	8 April 2022
Primary completion	8 April 2023
Estimated completion	8 April 2024

Drugs / interventions tested

Fluid MAX group

Conditions studied

Patients With Radiological, Clinical and Anamnestic Picture Compatible With a New Diagnosis of Glioblastoma — all drugs for Patients With Radiological, Clinical and Anamnestic Picture Compatible With a New Diagnosis of Glioblastoma →

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full company profile →

Who can join

Adults 18 to 90, any sex, with Patients With Radiological, Clinical and Anamnestic Picture Compatible With a New Diagnosis of Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials

Trials by the same sponsor.

NCT07168850 — Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia · NA · recruiting
NCT06699095 — Home Rehabilitation As Continuity of Care in MS · NA · recruiting
NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
NCT06584097 — COMparative Performance of General Purpose Models · recruiting
NCT07427940 — Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05330559 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Last refreshed: 15 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05330559.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing